Shares of AstraZeneca Pharma India Ltd today fell as much as 5.7 per cent, after gaining 26.7 per cent in the last three sessions till Thursday.
Investors’ outpoint gains were due to increasing focus of the parent in listed unit vs 100 per cent unlisted subsidiary.
Recent launches and distribution deals have happened via AstraZeneca’s listed unit only.
AstraZeneca had launched a drug diabetes treatment on Thursday. The company has entered into a distribution deal with Sun Pharmaceutical Industries and Dr. Reddy’s Labs.